Dragonfly Announces Multi-Target Expansion of Research Collaboration with AbbVie
Updated: Sep 2, 2022
Dragonfly and AbbVie expand their existing collaboration in oncology and autoimmune disease to develop additional drug candidates in immune-mediated diseases using Dragonfly's proprietary Tri-specific NK cell Engager Therapy (TriNKET™) platform
WALTHAM, Mass., April 20, 2022 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, today announced an expansion of its research collaboration with AbbVie (NYSE: ABBV) to discover and develop Dragonfly's novel immunotherapies for new targets in autoimmune and fibrotic diseases. AbbVie successfully licensed its first TriNKET™ drug candidate from Dragonfly, part of a multi-target collaboration initiated in November 2019, in January 2021.
"AbbVie is committed to delivering transformative treatment options for patients suffering from autoimmune and fibrotic diseases," said Dr. Jonathon Sedgwick, Vice President and Global Head of Discovery Research at AbbVie. "We have seen strong progress in our current collaboration with Dragonfly focused on their triNKET technology and are pleased to expand our partnership to include additional immunology targets of interest to AbbVie."
"AbbVie is a global leader in treating immune-mediated diseases, and they continue to be a terrific partner" said Bill Haney, co-founder and chief executive officer of Dragonfly, "we look forward to building on our successful collaboration, and rapidly progressing with the AbbVie team to advance new treatment options for patients."
Under the agreement, Dragonfly will grant AbbVie the option to license exclusive worldwide intellectual property rights to multiple new candidates developed using Dragonfly's TriNKET™ technology platform. AbbVie will pay Dragonfly an upfront payment, future success-based milestone payments and royalties.
About Dragonfly
Dragonfly Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel TriNKET™ technology to harness the body's innate immune system to bring breakthrough treatments to patients.
For more information visit: www.dragonflytx.com https://www.linkedin.com/company/dragonfly-therapeutics-inc https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT:
Anne Deconinck | anne@dragonflytx.com
Related Links http://www.dragonflytx.com
SOURCE Dragonfly Therapeutics, Inc.
Pool enclosure technology continues to evolve as manufacturers develop new materials, operating mechanisms, and design approaches. Modern systems may include smoother tracks, improved sealing, automated controls, durable framing, and enhanced transparent panels. These features can make enclosures easier to operate and maintain compared with older designs. When exploring options, property owners should compare the technical specifications of different systems rather than focusing only on appearance. A https://www.coversinplay.com suitable design should match the property's needs and expected frequency of use. i like this post.
Custom boxes for clothing and apparel can be designed around folded garments, accessories, footwear, or coordinated product sets. Mailer boxes and folding cartons are common structures that can be adjusted to different dimensions. Inserts or tissue-compatible interiors may be incorporated when presentation is important. Manufacturers can also provide printing and finishing options for retail or online businesses. Proper boxes4products.com sizing helps prevent garments from shifting excessively while creating packaging that is convenient for storage, shipping, and customer handling. i like this post.
A clear explanation of the account access process is helpful when someone is new to an online platform. The 91 club login information gives readers a simple starting point for understanding how the sign-in section works. I also think it is useful to verify the website address before entering account details, especially when similar pages can appear in search results.
mình có lần lướt đọc mấy trao đổi trên mạng شيخ روحاني thì thấy nhắc nên cũng tò mò mở ra xem thử cho biết. mình không tìm hiểu sâu chỉ xem qua trong thời gian ngắn để quan sát bố cục cách sắp xếp جلب الحبيب các mục và trình bày nội جلب الحبيب dung tổng thể. cảm giác là các phần được trình bày khá gọn, các hurentest berlin mục rõ ràng Huren Berlin nên đọc lướt cũng không bị rối với mình như vậy là đủ để nắm tin cơ bản rồi. جلب الحبيب
👍
As a reader with an interest in biomedicine, I view AbbVie’s decision to elevate its partnership with Dragonfly as a highly strategic move to expand its immuno-oncology portfolio. This collaboration is akin to a high-level game of dordle: rather than solving just a single puzzle, the parties must employ strategic thinking to decipher and conquer two complex objectives simultaneously in order to maximize success.